News

Theralase(R) Closes $CAN 750,000 Non-Brokered Private Placement

TORONTO, ON / ACCESSWIRE / April 24, 2024 / Theralase® Technologies Inc. ("Theralase®" or the "Company") (TSXV:TLT)(OTCQB:TLTFF)(FRA:TTX), a clinical stage…

2 years ago

Nutriband Closes $8.4M Private Placement for Commercial Development of Aversa(R) Fentanyl Transdermal Patch Through FDA Submission

Private Placement of $8.4 million has closed and will fund the commercial development of lead product AVERSA Fentanyl to NDA…

2 years ago

Novo Nordisk A/S – Articles of Association, April 2024

Novo Nordisk's Articles of Association, April 2024 Attachment Articles of Association 24 Apr 2024

2 years ago

Tryp Therapeutics Provides Update on Plan of Arrangement With Exopharm Limited and Announces Voluntary Trading Halt

KELOWNA, BC / ACCESSWIRE / April 24, 2024 / Tryp Therapeutics, Inc. ("Tryp" or the "Company") (CSE:TRYP)(OTCQB:TRYPF) is pleased to…

2 years ago

TVM Capital Healthcare Announces EUR 16 Million Investment into neurocare

neurocare is revolutionizing mental health care by providing innovative methods and tools based on neurostimulation and other technologies to help…

2 years ago

NeuroNexus is Leveraging Bioz’s AI-Powered Citation Tools to Drive Increased Sales Conversion

PALO ALTO, CA / ACCESSWIRE / April 24, 2024 / Bioz, Inc., a Silicon Valley AI company, has partnered with…

2 years ago

Senzime Wins Another Major US Veterans Affairs Contract; Expands Reach of TetraGraph System

UPPSALA, SE / ACCESSWIRE / April 24, 2024 / Senzime (STO:SEZI)(OTCQX:SNZZF) Senzime, an industry leader in perioperative precision-based patient monitoring…

2 years ago

Spago Nanomedical Reports Favorable Data in Breast Cancer Model with Tumorad

LUND, SWEDEN / ACCESSWIRE / April 24, 2024 / Spago Nanomedical (STO:SPAGO.ST)(FRA:7UX.F) Spago Nanomedical AB (publ) announced today data from…

2 years ago

Angle PLC Announces New Commercial Agreement with AstraZeneca

ANGLE signs agreement to tailor existing Parsortix-based DNA damage response assay for use in pharmaceutical R&D GUILDFORD, SURREY / ACCESSWIRE…

2 years ago

Interim Report January-March 2024

GOTHENBURG, SWEDEN / ACCESSWIRE / April 24, 2024 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV)First quarter 2024 (Jan 1 - Mar 31)•…

2 years ago